Signal #150720 · SEC 8-K

$STLN SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $STLN filing catalyst

Why did $STLN trigger an AI stock catalyst alert?

$STLN triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.0/10). Headline: Starling Oncology Reports Q3 Revenue of $169.8M (+24.3%), Narrows FY26 Revenue and FCF Guidance. Key points: - Consolidated Q3 revenue increased 24.3% YoY to $169.8M, gross profit rose to $30.7M. - FY2026 revenue guidance top-end lowered to $650-$660M (prior $650-$670M); FCF trimmed to $5-$10M (prior $5-$15M). - Medical loss ratio relating to capitated contracts worsened to 81.0% vs. 67.8% YoY.

How did $STLN stock react after the SEC filing?

After the SEC 8-K for $STLN, observed market reaction: T0 price $6.70. Past moves do not guarantee future results.

Where can I get real-time $STLN SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $STLN via Telegram and the VIP Web Terminal from €10/month.

$STLN

$STLN – Starling Oncology Reports Q3 Revenue of $169.8M (+24.3%), Narrows FY26 Revenue and FCF Guidance

Starling Oncology, Inc.

2026-11-05 00:00:00 UTC · SEC 8-K · All $STLN

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-2.0 / 10)

Consolidated Q3 revenue increased 24.3% YoY to $169.8M, gross profit rose to $30.7M.
FY2026 revenue guidance top-end lowered to $650-$660M (prior $650-$670M); FCF trimmed to $5-$10M (prior $5-$15M).
Medical loss ratio relating to capitated contracts worsened to 81.0% vs. 67.8% YoY.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →